JW Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
JW Pharmaceutical has a total shareholder equity of ₩283.5B and total debt of ₩123.3B, which brings its debt-to-equity ratio to 43.5%. Its total assets and total liabilities are ₩663.9B and ₩380.4B respectively. JW Pharmaceutical's EBIT is ₩93.2B making its interest coverage ratio 15.5. It has cash and short-term investments of ₩107.7B.
Key information
43.5%
Debt to equity ratio
₩123.32b
Debt
| Interest coverage ratio | 15.5x |
| Cash | ₩107.71b |
| Equity | ₩283.48b |
| Total liabilities | ₩380.41b |
| Total assets | ₩663.89b |
Recent financial health updates
JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly
Aug 07
Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?
Feb 15Recent updates
JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly
Aug 07JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality
Mar 21Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?
Apr 08How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?
Mar 13Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?
Feb 15JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.
Jan 19
Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend
Dec 24Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?
Nov 30Financial Position Analysis
Short Term Liabilities: A001060's short term assets (₩392.7B) exceed its short term liabilities (₩292.7B).
Long Term Liabilities: A001060's short term assets (₩392.7B) exceed its long term liabilities (₩87.7B).
Debt to Equity History and Analysis
Debt Level: A001060's net debt to equity ratio (5.5%) is considered satisfactory.
Reducing Debt: A001060's debt to equity ratio has reduced from 77.5% to 43.5% over the past 5 years.
Debt Coverage: A001060's debt is well covered by operating cash flow (97.5%).
Interest Coverage: A001060's interest payments on its debt are well covered by EBIT (15.5x coverage).